Study S002349

A Randomized, Double-Blind, Placebo-controlled Study of Efsubaglutide Alfa on Weight Management in Subjects With Overweight or Obesity to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics, and Efficacy.

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06732960
Acronym: LIGHT
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: DOUBLE
Status: COMPLETED
Enrollment: 50
Start: 2024-04-21
Primary completion: 2024-11-18
Lead sponsor: Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Conditions: Overweight or Obesity
Interventions: BIOLOGICAL:Efsubaglutide Alfa; OTHER:Placebo
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: OTHER:YN011-W201

Registered primary outcomes

Weight [Baseline, 4 weeks after the target dose]
Adverse Event [Adverse events occurring within 4 weeks of the last dose from baseline]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0047758	738-P: Efficacy and Safety of Efsubaglutide Alfa in Patients with Obesity or Overweight—A Phase 2 Study Yuqian Bao, Diabetes	2025	Randomized trial	DOI	cites ClinicalTrials.gov:NCT06732960